Yuezhen Deng

Yuezhen Deng

Auto-generated profile, based on publicly available information

Yuezhen Deng

Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
CZChenxi Zhong
Chenxi Zhong
GXGuosheng Xiong
Guosheng Xiong
Haitang YangHaitang Yang
Haitang Yang
XDXiaohua Du
Xiaohua Du
JDJiankui Du
Jiankui Du
YDYuezhen Deng
Yuezhen Deng
Inflammation and metabolic reprogramming are hallmarks of cancer. How inflammation regulates cancer metabolism remains poorly understood. In this study, we found that 3-hydroxy-3-methylglutaryl-CoA lyase (HMGCL), the enzyme that catalyzes the catabolism of leucine and promotes the synthesis of ketone bodies, was downregulated in lung cancer. Downregulation of HMGCL was associated with a larger tumor size and a shorter overall survival time. In a functional study, overexpression of HMGCL increased the content of β-hydroxybutyrate (β-HB) and inhibited the tumorigenicity of lung cancer cells, and deletion of HMGCL promoted de novo tumorigenesis in KP (KrasG12D;P53f/f) mice. Mechanistically, tumor necrosis factor α (TNFα) treatment decreased the HMGCL protein level, and IKKβ interacted with HMGCL and phosphorylated it at Ser258, which destabilized HMGCL. Moreover, NEDD4 was identified as the E3 ligase for HMGCL and promoted its degradation. In addition, mutation of Ser258 to alanine inhibited the ubiquitination of HMGCL by NEDD4 and thus inhibited the anchorage-independent growth of lung cancer cells more efficiently than did wild-type HMGCL. In summary, this study demonstrated a link between TNFα-mediated inflammation and cancer metabolism.

22 July 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
XSXi Su
Xi Su
FLFeng Liang
Feng Liang
YZYa Zeng
Ya Zeng
ZYZhang-Ru Yang
Zhang-Ru Yang
YDYue-Zhen Deng
Yue-Zhen Deng
XCXuwei Cai
Xuwei Cai
This study sought to explore potential roles of endothelial ferroptosis in radiation-associated atherosclerosis (RAA) and molecular mechanisms behind this phenomenon. Here, an in vivo RAA mouse model was used and treated with ferroptosis inhibitors. We found that the RAA group had a higher plaque burden and a reduction in endothelial cells with increased lipid peroxidation compared to the control group, while ameliorated by liproxstatin-1. In vitro experiments further confirmed that radiation induced the occurrence of ferroptosis in human artery endothelial cells (HAECs). Then, proteomics analysis of HAECs identified domain-containing protein 2 (DDHD2) as a co-differentially expressed protein, which was enriched in the lipid metabolism pathway. In addition, the level of lipid peroxidation was elevated in DDHD2-knockdown HAECs. Mechanistically, a significant decrease in the protein and mRNA expression of glutathione peroxidase 4 (GPX4) was observed in HAECs following DDHD2 knockdown. Co-immunoprecipitation assays indicated a potential interaction between DDHD2 and nuclear factor erythroid 2-related factor 2 (Nrf2). The downregulation of Nrf2 protein was also detected in DDHD2-knockdown HAECs. In conclusion, our findings suggest that radiation-induced endothelial ferroptosis accelerates atherosclerosis, and DDHD2 is a potential regulatory protein in radiation-induced endothelial ferroptosis through the Nrf2/GPX4 pathway.

1 March 2025 in Oncogene
Verified
Journal Article
Closed access
PDF file
ZLZhi Li
Zhi Li
YGYidi Guan
Yidi Guan
JGJie Gao
Jie Gao
LZLan Zhu
Lan Zhu
ZZZimei Zeng
Zimei Zeng
YDYuezhen Deng
Yuezhen Deng

31 March 2023
Verified
Other
Open access
XLXiaoyu Liu
Xiaoyu Liu
ZLZhi Li
Zhi Li
ZWZhongmin Wang
Zhongmin Wang
FLFei Liu
Fei Liu
LZLinling Zhang
Linling Zhang
XWXiaojing Wang
Xiaojing Wang
ARID1A is a key mammalian SWI/SNF complex subunit that is mutated in 5% to 11% of lung cancers. Although recent studies have elucidated the mechanism underlying dysregulation of the switch/sucrose non-fermentable (SWI/SNF) complexes in cancers, the significance of ARID1A loss and its implications in lung cancers remain poorly defined. This study investigates how ARID1A loss affects initiation and progression of lung cancer. In genetically engineered mouse models bearing mutant Kras and a deficient Trp53 allele (KP), ARID1A loss (KPA) promoted lung tumorigenesis. Analysis of the transcriptome profiles of KP and KPA tumors suggested enhanced glycolysis following ARID1A loss, and expression of the glycolytic regulators Pgam1, pyruvate kinase M (Pkm), and Pgk1 was significantly increased in ARID1A-deficient lung tumors. Furthermore, ARID1A loss increased chromatin accessibility and enhanced hypoxia-inducible factor-1α (HIF1α) binding to the promoter regions of Pgam1, Pkm, and Pgk1. Loss of ARID1A in lung adenocarcinoma also resulted in loss of histone deacetylase 1 (HDAC1) recruitment, increasing acetylation of histone-4 lysine at the promoters of Pgam1, Pkm, and Pgk1, and subsequently enhancing BRD4-driven transcription of these genes. Metabolic analyses confirmed that glycolysis is enhanced in ARID1A-deficient tumors, and genetic or pharmacologic inhibition of glycolysis inhibited lung tumorigenesis in KPA mice. Treatment with the small molecule bromodomain and extraterminal protein (BET) inhibitor JQ1 compromised both initiation and progression of ARID1A-deficient lung adenocarcinoma. ARID1A negatively correlated with glycolysis-related genes in human lung adenocarcinoma. Overall, ARID1A loss leads to metabolic reprogramming that supports tumorigenesis but also confers a therapeutic vulnerability that could be harnessed to improve the treatment of ARID1A-deficient lung cancer.Significance:This study links ARID1A loss with enhanced glycolysis in lung cancer and demonstrates the preclinical efficacy of BET inhibitor therapy as a strategy to combat tumor growth.

31 March 2023
Verified
Other
Open access
XLXiaoyu Liu
Xiaoyu Liu
ZLZhi Li
Zhi Li
ZWZhongmin Wang
Zhongmin Wang
FLFei Liu
Fei Liu
LZLinling Zhang
Linling Zhang
XWXiaojing Wang
Xiaojing Wang
Supplementary Table from Chromatin Remodeling Induced by ARID1A Loss in Lung Cancer Promotes Glycolysis and Confers JQ1 Vulnerability

30 March 2023
Verified
Other
Open access
XJXiao-Dan Ji
Xiao-Dan Ji
GLGuo Li
Guo Li
Yuxiong FengYuxiong Feng
Yuxiong Feng
JZJiang-Sha Zhao
Jiang-Sha Zhao
JLJing-Jing Li
Jing-Jing Li
Dong XieDong Xie
Dong Xie
Supplementary Figure 5 from EphB3 Is Overexpressed in Non–Small-Cell Lung Cancer and Promotes Tumor Metastasis by Enhancing Cell Survival and Migration